KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Retained Earnings (2020 - 2025)

Historic Retained Earnings for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$2.0 billion.

  • Recursion Pharmaceuticals' Retained Earnings fell 5384.62% to -$2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 billion, marking a year-over-year decrease of 5384.62%. This contributed to the annual value of -$1.4 billion for FY2024, which is 4791.76% down from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Retained Earnings stood at -$2.0 billion, which was down 5384.62% from -$1.8 billion recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Retained Earnings ranged from a high of -$244.3 million in Q1 2021 and a low of -$2.0 billion during Q3 2025
  • For the 5-year period, Recursion Pharmaceuticals' Retained Earnings averaged around -$908.7 million, with its median value being -$781.6 million (2023).
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Retained Earnings crashed by 8730.25% in 2021, and later crashed by 4791.76% in 2024.
  • Recursion Pharmaceuticals' Retained Earnings (Quarter) stood at -$400.1 million in 2021, then crashed by 59.86% to -$639.6 million in 2022, then tumbled by 51.3% to -$967.6 million in 2023, then crashed by 47.92% to -$1.4 billion in 2024, then tumbled by 39.73% to -$2.0 billion in 2025.
  • Its Retained Earnings was -$2.0 billion in Q3 2025, compared to -$1.8 billion in Q2 2025 and -$1.6 billion in Q1 2025.